FDA Approves Roche's Susvimo as First Continuous-Delivery Therapy for Diabetic Retinopathy
核心洞察
The FDA approved Roche's Susvimo (ranibizumab injection) 100 mg/mL in May 2025 as the first continuous-delivery therapy for diabetic retinopathy (搜索), requiring only one refill every nine months.
The approval was supported by positive data from the Phase III Pavilion trial and applies to patients who have previously responded to at least two anti-VEGF (搜索) injections.
Diabetic retinopathy (搜索) affects nearly 10 million people in the US and over 100 million worldwide, with prevalence rising with age and affecting 15–30% of the diabetic population.
Roche has secured FDA approval for Susvimo (ranibizumab injection) at a 100 mg/mL dose for the treatment of diabetic retinopathy (搜索), marking a significant milestone as the first and only continuous-delivery therapy approved by the agency for this indication. The approval, announced in May 2025, offers a new treatment paradigm for the nearly 10 million people in the US and over 100 million worldwide affected by this serious eye condition.
Susvimo is now available in the US for retina specialists and patients with diabetic retinopathy (搜索) who have previously shown a positive response to at least two anti-vascular endothelial growth factor (anti-VEGF (搜索)) injections. The therapy is designed to preserve vision with only one refill required every nine months, representing a substantial departure from the frequent intravitreal injection schedules that characterize current standard-of-care anti-VEGF treatments.
Clinical Evidence Supporting Approval
The FDA's decision was supported by positive data from the Phase III Pavilion trial (NCT04503551), which demonstrated Susvimo's ability to preserve vision in patients with diabetic retinopathy (搜索). The continuous-delivery mechanism of the implant distinguishes Susvimo from conventional anti-VEGF (搜索) therapies such as ranibizumab (LUCENTIS) and aflibercept (EYLEA), which require more frequent intravitreal injections and can contribute to reduced patient adherence over time.
Disease Burden and Epidemiology
Diabetic retinopathy (搜索) remains a leading cause of vision loss among working-age populations in the US and many other countries. According to CDC data cited in the DelveInsight market report, the prevalence of diabetic retinopathy in the US rises with age, affecting 13% of individuals under 25 and increasing to 28.4% among those aged 65–79. Among adults aged 40 and above, approximately 8.94 million are affected, with 1.71 million experiencing vision-threatening complications.
Globally, the burden is substantial. Diabetic retinopathy (搜索) affects approximately 3%–4.1% of the European population, with prevalence in those over age 60 highest in France, followed by Germany. In Japan, the condition affects around 3 million individuals, ranking as the third leading cause of visual impairment. At any given point, 15–30% of the diabetic population suffers from some form of diabetic retinopathy, yet approximately half of patients remain unaware of their condition due to a lack of symptoms and mild non-proliferative disease that may go undetected.
Evolving Competitive Landscape
The diabetic retinopathy (搜索) market is poised for strong expansion through 2036, according to DelveInsight's market analysis. The pipeline features multiple emerging therapies across various mechanisms of action. In November 2025, Ocular Therapeutix randomized the first patient in the Phase 3 HELIOS-3 registrational study evaluating AXPAXLI (OTX-TKI) for non-proliferative diabetic retinopathy. Kodiak Sciences reported positive topline results in the GLOW2 Phase III superiority study of ZENKUDA (tarcocimab tedromer, KSI-301), an anti-VEGF (搜索) intravitreal biologic built on the company's proprietary antibody biopolymer conjugate platform, in March 2026.
REGENXBIO, in collaboration with AbbVie (搜索), plans to report topline data from the pivotal ATMOSPHERE and ASCENT trials evaluating sura-vec (ABBV-RGX-314) via subretinal delivery in Q4 2026, with global regulatory submissions anticipated in 2027. In June 2025, Perfuse Therapeutics (搜索) announced positive outcomes from two Phase 2 clinical trials of PER-001, a first-in-class endothelin antagonist delivered via a slow-release, dissolvable implant injected every six months, showing significant improvement in vision compared to control groups in both glaucoma and diabetic retinopathy (搜索).
Market Dynamics
Key drivers of market growth include the rising global prevalence of diabetes, an expanding aging population, growing awareness of the importance of regular retinal screening, and advancements in retinal imaging technologies including OCT, fundus photography, and AI-powered diagnostic tools. The increasing adoption of anti-VEGF (搜索) therapies and sustained-release treatment approaches is also enhancing clinical outcomes.
However, barriers persist. High treatment costs and limited reimbursement in certain regions can restrict patient access to advanced therapies. Frequent intravitreal injections and long-term treatment requirements may reduce patient adherence. Delayed diagnosis and inadequate screening coverage, particularly in low- and middle-income countries, continue to limit timely intervention. Additionally, a shortage of trained ophthalmologists and retinal specialists in many regions poses challenges to effective disease management.
The approval of Susvimo represents a meaningful advance in addressing the treatment burden associated with diabetic retinopathy (搜索), offering patients a continuous-delivery option that reduces the frequency of clinical visits while maintaining vision-preserving efficacy.